From The Industry Experts

  1. Early-Stage Biotech's AI Advantage Is A Window That Closes 5/27/2026

    FDA AI guidance won’t build your strategy for you. Learn how biotech teams can avoid retrofits and design smarter clinical AI from day one.

  2. Meeting The FDA's New Real-World Evidence Standards 5/27/2026

    FDA guidance is reshaping RWE strategy. Sponsors that build interoperable, audit-ready RWD infrastructure now will be best positioned for faster, defensible submissions.

  3. Where PRO Strategy Goes Wrong 5/27/2026

    PRO and COA strategy is now central to trial success. Organizations that capture meaningful patient experience data will gain stronger evidence and a regulatory advantage.

  4. Is The Industry Ready To Trust LLMs With Chart Review? 5/27/2026

    See how LLM-powered extraction transforms unstructured medical records into compliant, audit-ready clinical data with machine-scale speed, human oversight, and regulatory-grade accuracy.

  5. The eCOA Iceberg 5/27/2026

    Understand the true cost of eCOA deployment, beyond software licenses, to reduce protocol risk, avoid operational bottlenecks, and protect study timelines and data quality.

  6. Navigating The Challenges Of Large, International Phase III Breast Cancer Trials 5/27/2026

    In the competitive landscape of breast cancer research, aligning biomarker testing, regulatory pathways, and regional operations from day one creates a path to faster enrollment and stronger outcomes.

  7. Artificial Intelligence, Virtual Participants, and the Evolving FDA Regulatory Landscape 5/27/2026

    Understanding emerging requirements around transparency, risk, and governance is essential for responsibly advancing AI-driven innovation in regulated environments.

  8. The ctDNA Clinical Trial Advantage 5/27/2026

    See how CROs are helping shape the future of ctDNA research—translating emerging data, regulatory insights, and biomarker innovation into faster, smarter oncology development.

  9. Mergers And Acquisitions: How Institutional Knowledge Protecting Value 5/27/2026

    M&A transitions can either preserve momentum or create costly setbacks. Learn how protecting institutional knowledge helps sponsors reduce risk, maintain continuity, and accelerate development.

  10. Simultaneous Submissions And Managing Multiple Regulatory Pathways 5/27/2026

    Global regulators are increasingly aligned, creating new opportunities for sponsors to pursue near-simultaneous submissions across major markets